These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 16292882)

  • 21. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.
    Ballangrud AM; Yang WH; Palm S; Enmon R; Borchardt PE; Pellegrini VA; McDevitt MR; Scheinberg DA; Sgouros G
    Clin Cancer Res; 2004 Jul; 10(13):4489-97. PubMed ID: 15240541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells.
    Jung Y; Park HJ; Kim PH; Lee J; Hyung W; Yang J; Ko H; Sohn JH; Kim JH; Huh YM; Yun CO; Haam S
    J Control Release; 2007 Nov; 123(2):164-71. PubMed ID: 17854941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [HER-2/neu positive breast cancer: how to prescribe adjuvant trastuzumab (Herceptin)?].
    Belkacémi Y; Gligorov J; Mauriac L; Azria D
    Bull Cancer; 2006 Oct; 93(10):991-9. PubMed ID: 17074658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
    Chan CT; Metz MZ; Kane SE
    Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HER2/neu antibody conjugated poly(amino acid)-coated iron oxide nanoparticles for breast cancer MR imaging.
    Yang HM; Park CW; Woo MA; Kim MI; Jo YM; Park HG; Kim JD
    Biomacromolecules; 2010 Nov; 11(11):2866-72. PubMed ID: 20932000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy.
    Bellone S; Palmieri M; Gokden M; Joshua J; Roman JJ; Pecorelli S; Cannon MJ; Santin AD
    Gynecol Oncol; 2003 Oct; 91(1):231-40. PubMed ID: 14529687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
    Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
    Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multicomponent Conjugates of Anticancer Drugs and Monoclonal Antibody with PAMAM Dendrimers to Increase Efficacy of HER-2 Positive Breast Cancer Therapy.
    Marcinkowska M; Stanczyk M; Janaszewska A; Sobierajska E; Chworos A; Klajnert-Maculewicz B
    Pharm Res; 2019 Sep; 36(11):154. PubMed ID: 31482205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of breast cancer cells using targeted magnetic nanoparticles and ultra-sensitive magnetic field sensors.
    Hathaway HJ; Butler KS; Adolphi NL; Lovato DM; Belfon R; Fegan D; Monson TC; Trujillo JE; Tessier TE; Bryant HC; Huber DL; Larson RS; Flynn ER
    Breast Cancer Res; 2011 Nov; 13(5):R108. PubMed ID: 22035507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.
    Viani GA; Afonso SL; Stefano EJ; De Fendi LI; Soares FV
    BMC Cancer; 2007 Aug; 7():153. PubMed ID: 17686164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
    Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production.
    Simeone AM; Broemeling LD; Rosenblum J; Tari AM
    Oncogene; 2003 Oct; 22(43):6739-47. PubMed ID: 14555987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells.
    Xu H; Yu Y; Marciniak D; Rishi AK; Sarkar FH; Kucuk O; Majumdar AP
    Mol Cancer Ther; 2005 Mar; 4(3):435-42. PubMed ID: 15767552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents.
    Funovics MA; Kapeller B; Hoeller C; Su HS; Kunstfeld R; Puig S; Macfelda K
    Magn Reson Imaging; 2004 Jul; 22(6):843-50. PubMed ID: 15234453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
    Emens LA
    Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-HER2 antibody and ScFvEGFR-conjugated antifouling magnetic iron oxide nanoparticles for targeting and magnetic resonance imaging of breast cancer.
    Chen H; Wang L; Yu Q; Qian W; Tiwari D; Yi H; Wang AY; Huang J; Yang L; Mao H
    Int J Nanomedicine; 2013; 8():3781-94. PubMed ID: 24124366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications.
    Villella JA; Cohen S; Smith DH; Hibshoosh H; Hershman D
    Int J Gynecol Cancer; 2006; 16(5):1897-902. PubMed ID: 17009989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.
    Gonzalez-Angulo AM; Hortobágyi GN; Esteva FJ
    Oncologist; 2006 Sep; 11(8):857-67. PubMed ID: 16951389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo breast cancer characterization imaging using two monoclonal antibodies activatably labeled with near infrared fluorophores.
    Sano K; Mitsunaga M; Nakajima T; Choyke PL; Kobayashi H
    Breast Cancer Res; 2012; 14(2):R61. PubMed ID: 22510481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiation binary targeted therapy for HER-2 positive breast cancers: assumptions, theoretical assessment and future directions.
    Mundy DW; Harb W; Jevremovic T
    Phys Med Biol; 2006 Mar; 51(6):1377-91. PubMed ID: 16510950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.